Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD-Reference-Cited by-同舟云学术

Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD

Published:2019 Issue:1 Volume:15 Page:50-58
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

Cheng Zhujun¹²³,Wen Yusong¹²³,Liang Bowen⁴²³,Chen Siyang⁴²³,Liu Yujun⁵²³,Wang Zang⁴²³,Cheng Jiayu⁶²³,Tang Xiaoli⁷²³,Xin Hongbo¹²³,Deng Libin¹²³⁷²^ORCID

Affiliation:

1. Institute of Translational Medicine, Nanchang University

2. Nanchang

3. P. R. China

4. School of Public Health, Nanchang University

5. Queen Mary School, Medical College, Nanchang University

6. The Fourth Clinical Medical College, Nanchang University

7. College of Basic Medical Science, Nanchang University

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangxi Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/MO/C8MO00214B

Reference44 articles.

1. Non-alcoholic fatty liver disease

2. Effect of Trichostatin A on CNE2 Nasopharyngeal Carcinoma Cells - Genome-wide DNA Methylation Alteration

3. Reactive Oxygen Species-Induced TXNIP Drives Fructose-Mediated Hepatic Inflammation and Lipid Accumulation Through NLRP3 Inflammasome Activation

4. Epigenetic modifications by inhibiting histone deacetylases reverse memory impairment in insulin resistance induced cognitive deficit in mice

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression;Pathology - Research and Practice;2023-11

2. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients;Journal of Translational Medicine;2023-05-20

3. Deciphering the role of aberrant DNA methylation in NAFLD and NASH;Heliyon;2022-10

4. Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease;Pharmaceutical Biology;2022-09-20

5. A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies;Metabolites;2022-06-07